Clinical trialsCompany release

CG Oncology deck details cretostimogene bladder cancer data, FDA designations and manufacturing scale-up

🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026

The company's investor presentation covers its sole candidate, an unapproved oncolytic immunotherapy for NMIBC, citing no Grade 3 or higher treatment-related adverse events across three studies.

CG Oncology has published a corporate presentation centred on cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). It is the company's only product candidate, and no regulator has approved it.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): CG Oncology, Inc. ↗

Article written by VigiEye from the official source (CG Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →